Monoclonal antibodyPhase 3 trialInvestigational
Dinutuximab
How it works
Blocks the GD2 receptor on cancer cells, allowing immune cells to attack them.
Cancer types
Colorectal Cancer— All patients
Efficacy
In clinical trials, dinutuximab improved response rates and overall survival in patients with metastatic colorectal cancer.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.